Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 May;66(5):1101-1103.
doi: 10.1016/j.jhep.2016.12.028. Epub 2017 Feb 3.

Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C

Jason Grebely  1 , Tracy Swan  2 , Matthew Hickman  3 , Julie Bruneau  4 , Philip Bruggmann  5 , Olav Dalgard  6 , Alain Litwin  7 , Markus Backmund  8 , Gregory J Dore  9 ; International Network for Hepatitis in Substance Users
Affiliations
Comment

Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C

Jason Grebely et al. J Hepatol. 2017 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

JG is a consultant/advisor and has received research grants from Abbvie, Bristol Myers Squibb, Cepheid, Gilead Sciences and Merck. MH has received research grants from Gilead and honoraria from Abbvie, MSD, and Gilead. JB is a consultant and has received grants from Gilead Sciences and Merck. OD is a consultant/advisor Abbvie and Merck and has received research grants from Abbvie, Gilead and Merck. AL is a consultant/advisor from Abbvie, Bristol Myers Squibb, Gilead Sciences, Janssen, and Merck, and has received research grants from Gilead Sciences and Merck. GD is a consultant/advisor and has received research grants from Abbvie, Bristol Myers Squibb, Cepheid, Gilead, Merck, Janssen and Roche.

Comment in

Comment on

  • EASL Recommendations on Treatment of Hepatitis C 2016.
    European Association for the Study of the Liver. European Association for the Study of the Liver. J Hepatol. 2017 Jan;66(1):153-194. doi: 10.1016/j.jhep.2016.09.001. Epub 2016 Sep 22. J Hepatol. 2017. PMID: 27667367 No abstract available.

References

    1. Puoti M, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E, et al. ABT-450/r/ombitasvir plus dasabuvir with or without ribavirin in hcv genotype 1-infected patients receiving stable opioid substitution treatment: pooled analysis of efficacy and safety in phase 2 and phase 3 trials. Hepatology 2014;60:1135a–1136a.
    1. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594–1603. - PubMed
    1. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevirelbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015;163:1–13. - PubMed
    1. Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. In: Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 2016. - PMC - PubMed
    1. Grebely J, Mauss S, Brown A, Bronowicki JP, Puoti M, Wyles D, et al. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials. In: Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 2016. - PubMed